PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

By A. Afshar-Oromieh, A. Malcher, M. Eder, M. Eisenhut, H. Linhart, B. Hadaschik, T. Holland-Letz, F. Giesel, C. Kratochwil, S. Haufe and 2 more. European Journal of Nuclear Medicine and Molecular Imaging, 2013

890 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/5c1dba8125354c91c60274d710056bbe2a33ad29

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Afshar-Oromieh
2. M. Eiber
3. W. Fendler
4. C. Zechmann
5. A. Malcher
6. M. Eisenhut
7. H. Linhart
8. F. Giesel

Citations in the corpus

• Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer (2013, methodology): “Fifteen patients (3, 5–14, 16–17 and 19–20) of the present study have coincidentally been analysed in a different study evaluating the biodistribution of the PSMA tracer in humans [26].”
• 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 (2017, background): “may help to identify lesions in close proximity to the ureter or the bladder [8], or lesions with a low PSMA expression and slower accumulation of the tracer.”